Coronado Biosciences, Inc. 24 New England Executive Park Suite 105 Burlington,
MA 01803 United States - Map Phone: 781-652-4500 Fax: 781-652-4545 Website: http://www.coronadobiosciences.com
Coronado Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of immunotherapy biologic agents for the treatment of autoimmune diseases and cancer. Its principal pharmaceutical product candidates in clinical development include TSO or CNDO-201, which is a biologic comprising Trichuris suis ovathe, the microscopic eggs of the porcine whipworm, for the treatment of autoimmune diseases, such as Crohns disease, ulcerative colitis, multiple sclerosis, autism, psoriasis, type 1 diabetes, and rheumatoid arthritis; and CNDO-109, a biologic that activates the immune systems natural killer, cells to seek and destroy cancer cells, for the treatment of acute myeloid leukemia. Coronado Biosciences, Inc. has collaboration agreement with Dr. Falk Pharma GmbH and OvaMed GmbH for the development of TSO to treat Crohns disease. The company was founded in 2006 and is based in Burlington, Massachusetts. Key Statistics
| |
| Coronado Biosciences, Inc.’s ISS Governance QuickScore as of May 1, 2013 is 5. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 2; Compensation: 5. | | Brought to you by Institutional Shareholder Services (ISS) |
| | Pay | Exercised | Dr. Harlan F. Weisman M.D.,
61 Chairman and Chief Exec. Officer | 17.00K | 0.00 | Dr. Eric K. Rowinsky M.D.,
56 Vice Chairman and Consultant | 280.00K | N/A | Dr. Lucy Lu M.D.,
38 Chief Financial Officer and Exec. VP | 350.00K | 0.00 | Mr. Noah D. Beerman MBA,
51 Chief Operating Officer and Exec. VP | 464.00K | 0.00 | Mr. Dale Ritter ,
62 Chief Accounting Officer and Sr. VP of Fin. | 379.00K | 0.00 |
|
| | Amounts are as of Dec 30, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year. | | Currency in USD. |
|